



Übersicht Urologische Onkologische Studien

Diagnose	Studienkürzel	Studientitel	Sponsor	Studienphase	Rekrutierung	Vertragsbeginn	Vertragsende
lokal fortgeschrittenes oder metastasiertes Urothelkarzinom oder des Harntraktes	MO29983	An open label, single arm, multicenter, safety study of Atezolizumab in locally advanced or metastatic Urothelia or Non-Urothelia Carcinoma of the Uronary tract	Roche	IIIb	beendet	10/2016	Jan 22
Prostatakarzinom mit kardiovaskulärer Begleiterkrankung	PRONOUNCE	A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)	Ferring	IIIb	beendet	05/2019	31.07.2021
myoinvasives Urothelkarzinom	BLCA01	Eine Studie zum Vergleich der öffentlich verfügbaren Mutationsdaten (TCGA-The Cancer Genom Anatomy Project) mit denen in der regionalen Patientenpopulation unter Verwendung der Roche AVENION Kits und eines blasenspezifischen Sequenierpanels	Signature Diagnostics GmbH	klinisch-diagnostische Studie	laufend	02/2020	
Nierenzellkarzinom	WO41994	A Phase III, multicenter, randomized, open label study of Atezolizumab in combination with Cabozantinib in Patients with Advanced Renal Cell Carcinoma who experienced disease progression during of after Check Point Inhibitor Treatment	Roche	III	beendet	15.05.2020	
Nierenzellkarzinom	MK-6482-011	A Phase 3 Study of MK-6482 in Combination with Lenvatinib vs Cabozantinib for sekond line Treatment of RCC	MSD	III	laufend	04.05.2021	
myoinvasives Blasenkarzinom	MK3475-B15	A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)	MSD	III	laufend	14.05.2021	
myoinvasives Blasenkarzinom	BO42843	A Phase III, multicenter, randomized, open label study of Atezolizumab vs. Placebo as adjuv. therapy in patients with high-risk muscule-invasive bladder cancer who are CTDNA positive following cystectomy	Roche	III	12/2021	30.04.2021	